+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.

Age: 65Years +All GendersPhase 3
789 locations
T

Actively Recruiting

This research aims to evaluate the WeCan-Rural program, designed to help female breast cancer survivors in rural, medically underserved areas improve their health and reduce heart disease risk. The study focuses on survivors with stage I-III breast cancer who have completed treatment within the last five years and have a body mass index over 30. It will assess whether the program is acceptable, easy to follow, and helpful compared to standard care. Participants will be randomly assigned to either the WeCan-Rural program or receive standard health information from the National Cancer Institute. The WeCan-Rural program involves twelve weekly one-hour video sessions via Zoom led by a trained therapist, teaching skills for healthy eating, physical activity, symptom management, and building healthy habits. Participants will receive tools like a wireless activity tracker, scale, and blood pressure monitor and may be provided a tablet and data plan if needed. During the study, participants will visit their clinic twice about 12 weeks apart for weight, blood pressure, blood samples, and a walking test. They will complete online surveys about their health, diet, symptoms, physical activity, and confidence in managing their health. Researchers will measure satisfaction, acceptability, and changes in heart health indicators, weight, symptoms, diet, and physical activity. The study aims to follow participants for approximately 12 to 14 weeks after baseline.

Age: 18Years +FEMALEPhase Not Applicable
5 locations